As one of the critical risk factors for early-onset Alzheimer’s disease (AD), trisomy 21 not only increases amyloid precursor protein (APP) gene dosage but also promotes the amyloidogenic pathway in the AD human brain by altering APP processing (1–3) and amyloid plaque deposition in the AD mouse brain (4). Here, APP is linked to Alzheimer disease.